Coherus Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Nine Months Ended | ||||||
| · · September 30, | ||||||
| · · 2026 · · 2025 | ||||||
| Operating activities · · · · | ||||||
| Net income (loss) | | $(98,292) | | $205,667 | ||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | | | | ||
| Depreciation and amortization | | 2,596 | | 3,028 | ||
| Stock-based compensation expense | | 8,650 | | 14,182 | ||
| Impairment of out-license asset, net | | — | | 1,646 | ||
| Loss on debt extinguishment | | | 3,363 | | | 10,286 |
| (Gain) loss on Sale Transactions, net (Note 6) | | | 1,067 | | | (338,680) |
| Change in fair value of derivatives | | | — | | | 12,608 |
| Other non-cash adjustments, net | | | (11,282) | | | (5,352) |
| Changes in operating assets and liabilities: | | | | | ||
| Trade receivables, net | | 4,101 | | 101,895 | ||
| Inventory | | | (10,942) | | | (15,994) |
| Prepaids and other current and non-current assets | | | 1,647 | | | 1,453 |
| Accounts payable | | 4,987 | | (14,468) | ||
| Accrued rebates, fees and reserves | | (3,513) | | (89,114) | ||
| TSA related operating assets and liabilities, net | | (45,020) | | 12,641 | ||
| Accrued compensation | | (3,254) | | (4,959) | ||
| Accrued and other current and non-current liabilities | | (8,103) | | (13,636) | ||
| Net cash used in operating activities | | (153,995) | | (118,797) | ||
| | | | | | | |
| Investing activities | | | | | ||
| Purchases of investments in marketable securities | | (50,349) | | (89,576) | ||
| Proceeds from maturities of investments in marketable securities | | 104,126 | | 1,650 | ||
| Net cash received related to the Sale Transactions (Note 6) | | | — | | | 478,681 |
| Milestone payment to Junshi Biosciences | | | — | | | (12,500) |
| Other investing activities, net | | | (1,100) | | | (330) |
| Net cash provided by investing activities | | 52,677 | | 377,925 | ||
| | | | | | | |
| Financing activities | | | | | ||
| Proceeds from 2031 Term Loans, net of debt discount and issuance costs | | | 52,657 | | | — |
| Proceeds from issuance of common stock under Public Offering, net of issuance costs | | | 53,650 | | | — |
| Partial repayment of Revenue Purchase and Sale Agreement | | | — | | | (47,652) |
| Proceeds from purchases under the employee stock purchase plan | | | 202 | | | 188 |
| Repayment and redemption of 2026 Convertible Notes, including transaction costs | | | (121) | | | (233,185) |
| Repayment of 2029 Term Loan, including premiums and fees | | | (40,661) | | | — |
| Other financing activities, net | | | 53 | | | (1,137) |
| Net cash provided by (used in) financing activities | | 65,780 | | (281,786) | ||
| | | | | | | |
| Net decrease in cash, cash equivalents and restricted cash | | (35,538) | | (22,658) | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 89,119 | | 126,250 | ||
| Cash, cash equivalents and restricted cash at end of period | | $53,581 | | $103,592 | ||
** Coherus Oncology, Inc.**
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.